Evidence & Research Status
TOFA research entered the obesity conversation in August 2026, when a University of California, Berkeley team published findings in Science Advances describing a small molecule that reduced fat mass…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
TOFA research entered the obesity conversation in August 2026, when a University of California, Berkeley team published findings in Science Advances describing a small molecule that reduced fat mass in obese mice without the lean-mass loss that typically accompanies weight reduction. The compound is not a peptide, and the mechanism has little in common with the incretin drugs that dominate current metabolic research.
What TOFA Is — and What It Is Not
TOFA is 5-tetradecyloxy-2-furoic acid, a small-molecule inhibitor of acetyl-CoA carboxylase. This is a meaningful distinction for anyone tracking the metabolic field. Semaglutide, tirzepatide, retatrutide and cagrilintide are peptides — chains of amino acids that bind incretin or amylin receptors. TOFA is a synthetic organic molecule acting on an intracellular enzyme system. The two classes are not variations on a theme; they intervene at entirely different points in metabolism.
TOFA is not an approved drug in any jurisdiction, is not in clinical trials for obesity, and is not offered by Portal to Wellness. It is included in the Research Library because the mechanism it illustrates is likely to recur as the metabolic pipeline broadens beyond incretins.
The Mechanism: ACC Inhibition and Partial PPAR Activation
Investigators reported that TOFA acts on two fronts. It inhibits acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2), enzymes that catalyse an early committed step in fatty-acid synthesis. It also partially activates PPARα and PPARδ, nuclear receptors involved in regulating lipid handling and energy expenditure.
The combination is what drew attention. Suppressing fatty-acid synthesis while simultaneously engaging receptors associated with fat oxidation gives a mechanistic rationale for shifting the balance between energy storage and energy use — rather than simply reducing how much energy an animal consumes.
What the Mouse Study Reported
In mice with diet-induced obesity, researchers observed the following after oral administration of TOFA:
- An average reduction in body weight of approximately 18%, with the loss attributed primarily to fat mass
- No significant change in lean mass
- No significant change in food intake
- Up to roughly 18% greater cellular energy expenditure, with no increase in physical activity and no rise in body temperature
- Lower fasting glucose and insulin, and improved glucose tolerance
- Reduced liver fat
- Lower circulating triglycerides and cholesterol
The absence of a change in body temperature is worth noting on its own. Historically, compounds that raised energy expenditure did so through mechanisms that generated heat, which is a well-known route to toxicity. Findings indicated the expenditure increase here occurred without that signature.
Intake Versus Expenditure
Incretin-based compounds are understood to work substantially through reduced energy intake — slowed gastric emptying and altered appetite signalling. TOFA, in these animal experiments, did not reduce food intake at all; the effect appeared on the expenditure side of the equation.
| Incretin peptides (semaglutide, tirzepatide) | TOFA (preclinical) | |
|---|---|---|
| Molecule class | Peptide | Small molecule |
| Primary target | GLP-1 / GIP receptors | ACC1 and ACC2; partial PPARα/δ |
| Main reported lever | Reduced energy intake | Increased energy expenditure |
| Effect on food intake | Reduced | Not significantly changed (mice) |
| Lean mass | Absolute lean mass typically declines alongside fat | No significant change reported (mice) |
| Human evidence | Extensive randomised trial data | None |
Because the levers differ, the mechanisms are at least theoretically complementary rather than strictly competitive. That is a hypothesis generated by the mechanism, not a finding — no combination outcome in humans has been established.
What This Does Not Establish
The gap between this result and anything usable is very wide, and it is worth stating plainly.
- These are mice. Rodent metabolism differs from human metabolism in exposure, clearance and thermoregulation. Compounds that perform impressively in rodent obesity models have failed repeatedly at the translation step.
- No human efficacy data exists for TOFA in obesity.
- No human safety or tolerability profile exists. ACC is not a niche enzyme; it sits in central lipid metabolism, and sustained inhibition in humans has not been characterised here.
- Lean mass in a mouse study is not a claim about human muscle. Lean mass is a body-composition compartment that includes organ tissue, body water and bone, not solely skeletal muscle.
- A single publication is not a literature. Independent replication has not yet occurred.
The accurate framing is that TOFA produced promising metabolic effects in mouse models, and that human efficacy and safety have not been established. Anything stronger than that outruns the data.
Open Questions for Researchers
- Does the energy-expenditure effect persist beyond the study window, or does metabolic adaptation offset it as it commonly does with caloric restriction?
- How much of the observed benefit derives from ACC inhibition versus PPAR engagement, and can those contributions be separated?
- Does the preservation of lean mass reflect preserved skeletal muscle specifically, or other lean compartments?
- What does chronic ACC inhibition do to hepatic lipid handling over longer periods?
- Would a mechanism acting on expenditure retain its effect in a subject whose intake is simultaneously suppressed by an incretin compound?
Why This Belongs on a Watchlist
Ongoing TOFA research is a useful marker for a broader shift. The obesity pipeline is diversifying along two axes at once: delivery format, as oral small molecules such as orforglipron move alongside injectables, and mechanism, as approaches beyond appetite suppression attract investment. Tracking that second axis early — while distinguishing rigorously between animal findings, early human data and established evidence — is more useful than reacting to each new result as though it were a breakthrough.
Sources: UC Berkeley News, News-Medical, Inside Precision Medicine. Original research published in Science Advances.
TOFA is not sold by Portal to Wellness and is not available for purchase here. Compounds that are offered are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.